Erlotinib Withdrawn Phase 2 Trials for Psoriasis Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01006096Erlotinib for Treatment of Psoriasis